Negative pressure therapy was associated with decreased surgical site infection. Negative pressure therapy offers significant potential for quality improvement.
gery have plateaued for both ulcerative colitis (UC) and Crohn' s disease (CD) while significant concerns have been raised about increasing rates of peri-operative complications. [2][3][4] Anti-tumor necrosis factor (anti-TNF) medications, in particular infliximab, have been shown to increase rates or perioperative infectious complications although this data remains controversial. 3,[8][9][10] It has also been suggested that concerns about anti-TNF related surgical complications is at least in part responsible for the increased rate of 3 stage surgery for UC in the United States. 10 Vedolizumab is an α4β7 anti-integrin antibody that has been increasingly used in both UC and CD. The α4β7 inhibi-
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.